Get the Daily Brief

All action, no filler. BioBriefs delivers the industry’s 10 must-know updates, every morning.

Latest Biotech News

Late-stage psoriasis readout for an AI-designed oral drug

June 15, 2026

Takeda reported head-to-head clinical results showing its AI-designed once-daily psoriasis pill, zasocitinib, outperformed Bristol Myers Squibb’s Sotyktu in a Phase 3 trial. In company-reported...

Outpatient, off-the-shelf CAR T data at EHA

June 15, 2026

Legend Biotech USA presented early clinical evidence for LB-2501, an off-the-shelf CD19/CD20 dual-targeting CAR T cell program, aiming to enable outpatient use. At EHA2026, investigators reported...

Ebola vaccine development accelerated for a specific species

June 15, 2026

Moderna and CEPI moved an investigational mRNA vaccine program forward for Bundibugyo virus, a rarer Ebola species driving the ongoing outbreak in the Democratic Republic of the Congo and Uganda....

Therapeutic manufacturing and translational execution guidance

June 15, 2026

A new industry-focused piece lays out decision-making steps for accelerating the lab-to-clinic transition when moving an injectable molecule into humans. The guidance centers on how drug owners...

Biotech IPOs break records again

June 15, 2026

Parabilis Medicines set a new U.S. biotech IPO record after pricing a $770.5 million offering and debuting on Nasdaq. The company raised $670 million gross proceeds with an upsized share count and...

Series B funds mid-stage depression programs

June 15, 2026

HMNC Brain Health raised $50 million in a Series B to advance two psychiatry programs into mid-stage clinical studies. Medice, a family-owned German drugmaker, led the round with additional...

New CAR T-like platform direction: adaptive, walk-in-place DBS for Parkinson’s

June 15, 2026

Researchers at UCSF reported a deep brain stimulation approach for Parkinson’s disease that adapts in real time to a patient’s walking behavior. The team described the system as tailoring...

Rare pediatric disease priority pathway monetized and pipeline financed

June 15, 2026

Rocket Pharmaceuticals’ pediatric priority review voucher sale ties regulatory acceleration to cash runway for later-stage gene therapy development. The report links the $180 million non-dilutive...

Diagnostic workflow improvement: long-read sequencing in rare diseases

June 15, 2026

A Netherlands implementation study presented at ESHG reported that long-read genome sequencing, using PacBio technology, improves interpretation and reduces the need for follow-up...

Phase 3 psoriasis results for Takeda’s AI-designed TYK2 inhibitor

June 15, 2026

Takeda reported head-to-head Phase 3 data showing its AI-designed oral psoriasis drug, zasocitinib, achieved total skin clearance in more than 35% of patients at week 16. In the company’s...

Legend’s off-the-shelf CAR T moves toward outpatient dosing

June 15, 2026

Legend Biotech USA presented updated first-in-human CAR T data for LB-2501 at EHA2026, positioning the CD19/CD20 dual-targeting therapy as a potential first-in-class, off-the-shelf option that...

Rocket Pharma sells FDA priority review voucher to fund rare disease pipeline

June 15, 2026

Rocket Pharmaceuticals said it raised $180 million by selling an FDA drug review fast pass tied to an accelerated approval for Kresladi, a rare pediatric disease priority review voucher. Rocket...

Biotech IPO surge continues with Parabilis’ record listing

June 15, 2026

Parabilis Medicines set a new Wall Street biotech IPO record by pricing its offering at $20 per share and raising $770.5 million in gross proceeds, according to IPO coverage. The company’s upsized...

Moderna and CEPI accelerate Bundibugyo mRNA Ebola vaccine toward phase 1

June 15, 2026

Moderna is pushing an investigational mRNA vaccine against the Bundibugyo virus species linked to the ongoing Ebola outbreak in the Democratic Republic of the Congo and Uganda. The program...

Cell therapy innovation: partial reprogramming gene therapy treated first patient in glaucoma trial

June 15, 2026

Life Biosciences announced it has treated the first participant in a gene therapy trial aiming to partially reprogram aged cells to a younger-like state. The approach turns on three genes intended...

Mid-stage funding: HMNC Brain Health raises to advance two depression drugs

June 15, 2026

HMNC Brain Health raised $50 million in a Series B round to advance two psychiatry programs into mid-stage studies. Medice led the financing, with additional support from other backers,...

Diagnostic genomics adoption: Netherlands pushes long-read sequencing as first-tier test

June 15, 2026

Researchers from the Netherlands reported at ESHG that long-read genome sequencing as a first-tier diagnostic test may not substantially increase diagnostic yield versus short-read testing, but it...

Cancer therapeutics biology: YBX1 drives immune evasion in NSCLC bone metastases

June 15, 2026

New research identified Y-box binding protein 1 (YBX1) as a driver of immune-evasive features in non-small cell lung cancer bone metastases, laying groundwork for potential targeted strategies in...

Precision oncology prediction: integrating genetic origin data with tumor mutations improves survival forecasts

June 15, 2026

Researchers presented findings suggesting that a patient’s genetic ancestry can materially influence cancer progression and survival predictions when integrated with tumor analysis. The work,...

Psoriasis—Phase 3 readout and potential FDA filing

June 15, 2026

Takeda reported head-to-head Phase 3 results for its AI-designed oral psoriasis drug zasocitinib, claiming complete skin clearance in more than 35% of patients at 16 weeks. The company said the...